OH-GE-AEROSPACE
19.6.2024 08:01:30 CEST | Business Wire | Press release
GE AEROSPACE (GENERAL ELECTRIC COMPANY; NYSE: GE) announced today that, as part of a simplification project following the launch of GE Aerospace as an independent public company, it has submitted applications for the delisting of GE common stock (ISIN Code US3696043013) from Euronext Paris, the London Stock Exchange and the SIX Swiss Exchange (the “Delisting”). This action follows a comprehensive review of the trading volume, cost and administrative requirements related to these listings. Following the Delisting, GE Aerospace shares will continue to be traded on the New York Stock Exchange (“NYSE”), GE Aerospace’s primary listing exchange.
The following required information is provided in connection with the Delisting from Euronext Paris. The Delisting has been approved by the Listing Board of Euronext Paris S.A.
Information Regarding Delisting Procedure for Euronext Paris
A sales facility procedure (the “Sales Facility”) will be put in place from 21 June 2024 to 19 July 2024 (the “Sales Facility Period”) to allow shareholders to sell on the NYSE their GE Aerospace shares which are listed on Euronext Paris and held in the Euroclear France clearing system (the “GE Aerospace Euronext Shares”). GE Aerospace has appointed Uptevia to act as centralizing agent under the Sales Facility (the “Centralizing Agent”).
During the Sales Facility Period, shareholders with GE Aerospace Euronext Shares will have the following options:
- sell on a voluntary basis all or part of their GE Aerospace Euronext Shares on the NYSE by participating in the Sales Facility (described in more detail below); or
- retain all or part of their GE Aerospace Euronext Shares, which will continue to be traded on Euronext Paris during the entire Sales Facility Period until and including the trading day prior to the date of the Delisting.
The GE Aerospace Euronext Shares will be delisted from Euronext Paris on 25 July 2024 (the “Delisting Date”).
Shareholders not participating
Shareholders who do not wish to sell their GE Aerospace Euronext Shares under the Sales Facility or directly on Euronext Paris, or have otherwise taken no action by the Delisting Date, will be able to trade their GE Aerospace Euronext Shares on the NYSE, subject to the terms and conditions applied by their financial intermediaries.
Participating shareholders
Shareholders who wish to sell their GE Aerospace Euronext Shares on the NYSE under the Sales Facility should request their financial intermediaries to deliver their GE Aerospace Euronext Shares during the Sales Facility Period to the Centralizing Agent, pursuant to the procedure described below.
The GE Aerospace Euronext Shares delivered to the Centralizing Agent during the Sales Facility Period will be sold on the NYSE as from 26 July 2024 by a broker, at market prices prevailing at the time of the sale. The Centralizing Agent will calculate the average sale price of the GE Aerospace Euronext Shares and will be in charge of transferring the sale proceeds (which will be converted into euros from U.S. dollars by Uptevia) to the GE Aerospace shareholders participating in the Sales Facility once it has received the funds for the sale of all of the GE Aerospace Euronext Shares tendered under the Sales Facility.
GE Aerospace will pay the brokerage commissions on the NYSE for the sale of GE Aerospace Euronext Shares tendered pursuant to the Sales Facility, the fee of the Centralizing Agent and any applicable foreign exchange commission that would be incurred in connection with the Sales Facility.
The Sales Facility procedure is also described in a Euronext notice to be published on 19 June 2024.
No guarantee can be given by GE Aerospace or by the Centralizing Agent as to the price at which the GE Aerospace Euronext Shares tendered pursuant to the Sales Facility will be sold. The Sales Facility is being provided solely as an accommodation to holders of GE Aerospace Euronext Shares. Holders (and in particular individual investors) of GE Aerospace Euronext Shares may decide not to participate in the Sales Facility or may decide not to take any action, in which case no guarantee can be given on the terms, including costs, that would be applied by their financial intermediary after the Delisting. Individual investors are urged to consult their own investment advisors before deciding to participate or not in this process.
The contemplated timetable of the Sales Facility and the Delisting can be summarized as follows (it being specified that GE Aerospace reserves the right to amend this calendar):
Event |
Date |
Sales Facility |
|
Beginning of the Sales Facility |
21 June 2024 |
End of the Sales Facility |
19 July 2024 |
End of the centralization by Uptevia |
23 July 2024 |
Sale on the NYSE of the GE Aerospace Euronext Shares tendered in the Sales Facility |
As from 26 July 2024 |
Settlement of the proceeds of the Sales Facility to the relevant financial intermediary |
As soon as possible after receipt of the proceeds of the Sales Facility |
Delisting |
|
Last day of trading of GE Aerospace Euronext Shares on Euronext Paris |
24 July 2024 |
Delisting of GE Aerospace Euronext Shares on Euronext Paris |
25 July 2024 |
GE Aerospace shareholders participating in the Sales Facility are reminded that they acknowledge and accept (i) the risk implied from the change in the share market price and/or applicable exchange rates between the date on which their shares are delivered to Uptevia for participation in the Sales Facility and the receipt of the applicable average sale proceeds, and (ii) that from the time the GE Aerospace Euronext Shares are delivered to Uptevia, they will not be entitled to any subsequent dividend declared by GE Aerospace. They are also reminded that any orders to tender GE Aerospace Euronext Shares to the Sales Facility are irrevocable, as is the subsequent sale of such GE Aerospace Euronext Shares tendered on the NYSE.
Shareholders may request any additional information from their custodian and usual financial intermediary, who has received the details of the Delisting.
About GE AEROSPACE
GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 44,000 commercial and 26,000 military aircraft engines. With a global team of 52,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow and the future at www.geaerospace.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618573691/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
